INTRODUCTION {#s1}
============

Hepatitis C virus (HCV) is a blood-borne virus and its infection imposes a global health burden in both developed and developing countries \[[@R1]\]. HCV is a major cause of advanced liver-related outcomes such as cirrhosis, hepatocellular carcinoma and a growing spectrum of extra-hepatic complications such as dermatological, rheumatological and haematological disorders, as well as kidney insufficiency \[[@R2], [@R3]\]. It is estimated that nearly half of HCV-seropositive patients are diagnosed to experience at least one extra-hepatic complication \[[@R4]\]. There is competing evidence that HCV has the feasibility of entry and replication in kidney tissue, ending up with many severe endpoints such as acute interstitial nephritis and focal segmental sclerosis \[[@R5]\]. Echoing from epidemiological observations, there was a close relationship between HCV infection and chronic kidney disease (CKD), while current literature is teeming with inconsistent results, with positive association being reported in some \[[@R6], [@R7]\] but not all \[[@R8], [@R9]\] studies. CKD was defined as kidney damage (the presence of albuminuria) or decreased estimated glomerular filtration rate (eGFR \< 60 ml/min/1.73 m^2^). A previous meta-analysis by Fabrizi et al summarized the predisposition of HCV-infected patients to CKD and they failed to produce any observable significance \[[@R10]\]. More recently, Park et al \[[@R11]\] and Fabrizi et al \[[@R12]\] have separately conducted an updated meta-analysis of this project and demonstrated an increased risk for the development of CKD in HCV-infected patients compared to uninfected individuals. In view of these inconclusive findings, a comprehensive assessment is urgently required and we hence hypothesized that HCV infection was a significant risk factor for the development of CKD. To explore this hypothesis further, after *de novo* evaluation, we identified additional five articles in English-language literature that were not incorporated in previous meta-analyses \[[@R10]--[@R12]\]. In addition, considering the intractable confounding or recall bias inherited in cross-sectional studies, we determined to meta-analytically assess the predisposition of HCV infection to the occurrence and severity of CKD separately in cross-sectional and longitudinal studies, and further seek other possible interpretations for the obvious heterogeneity obsessing existing meta-analyses.

RESULTS {#s2}
=======

Eligible studies and characteristics {#s2_1}
------------------------------------

The selection process of all eligible studies is shown in [Supporting Figure S1](#SD1){ref-type="supplementary-material"}. A total of 545 articles were identified after searching four electronic databases with predefined key terms, and 22 eligible articles involving 12 longitudinal studies (1,972,044 subjects) and 15 cross-sectional studies (937,607 subjects) were finally analyzed \[[@R6]--[@R9], [@R13]--[@R30]\]. After treating the studies with different eGFR cutoffs (eGFR \< 60, \< 30, \< 15 ml/min/1.73m^2^) and/or proteinuria individually, there were 38 studies (5,077,110 subjects, 15 longitudinal studies and 23 cross-sectional studies) in the corresponding subgroup analysis and their study characteristics are presented in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}.

![The forest plot for the prevalence and incidence of CKD conferred by the presence of HCV infection\
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###### The baseline characteristics of all qualified studies enrolled in this meta-analysis

  Author (Index) (year)                 Country   Collection time   Cohort sample size   Included sample size   Definition               Median follow-up (years)   Unexposed   Exposed             
  ------------------------------------- --------- ----------------- -------------------- ---------------------- ------------------------ -------------------------- ----------- --------- --------- --------
  **Cross-sectional studies**                                                                                                                                                                       
  Liangpunsakul (2005)                  US        1988-1994         15,336               1,357                  Proteinuria              0                          995         75        362       45
  Huang et al (2006)                    Taiwan    2002-2004         10,975               8,571                  Proteinuria              0                          8,004       557       567       58
  Tsui et al (2006)                     US        1988-1994         34,000               15,029                 eGFR\<60 ml/min/1.73m2   0                          14,663      631       366       8
  Tsui et al (Proteinuria) (2006)       US        1988-1994         34,000               15,029                 Proteinuria              0                          14,663      1,760     366       55
  Dalrymple et al (2007)                US        1999-2004         39,574               25,782                 eGFR\<60 ml/min/1.73m2   0                          23,854      1,423     1,928     93
  Tsui et al (eGFR\<60) (C) (2007)      US        2000-2001         2,352,584            474,369                eGFR\<60 ml/min/1.73m2   0                          421,495     71,654    52,874    4,759
  Tsui et al (eGFR\<30) (C) (2007)      US        2000-2001         2,352,584            474,369                eGFR\<30 ml/min/1.73m2   0                          421,495     8,430     52,874    1,058
  Ishizaka et al (2008)                 Japan     2004-2006         12,535               12,405                 eGFR\<60 ml/min/1.73m2   0                          12,333      1,887     72        22
  Ishizaka et al (Proteinuria) (2008)   Japan     2004-2006         12,535               12,405                 Proteinuria              0                          12,333      1,157     72        14
  Moe et al (C.-C.) (2008)              US        1994-2004         19,303               13,139                 eGFR\<60 ml/min/1.73m2   0                          9,201       745       3,938     248
  Asrani et al (eGFR\<60) (C) (2010)    US        2003-2006         6,000,000            167,569                eGFR\<60 ml/min/1.73m2   0                          154,185     8,172     13,384    682
  Asrani et al (eGFR\<30) (C) (2010)    US        2003-2006         6,000,000            167,569                eGFR\<30 ml/min/1.73m2   0                          154,185     370       13,384    29
  Asrani et al (eGFR\<15) (C) (2010)    US        2003-2006         6,000,000            167,569                eGFR\<15 ml/min/1.73m2   0                          154,185     123       13,384    13
  Gordon et al (2010)                   US        1997-2006         79,492               67,063                 eGFR\<60 ml/min/1.73m2   0                          64,006      6,666     3,057     443
  Lee et al (eGFR\<60) (2010)           Taiwan    2004              55,780               49,048                 eGFR\<60 ml/min/1.73m2   0                          43,859      6,249     5,189     994
  Lee et al (eGFR\<30) (2010)           Taiwan    2004              55,780               49,048                 eGFR\<30 ml/min/1.73m2   0                          43,859      333       5,189     56
  Lee et al (Proteinuria) (2010)        Taiwan    2004              55,780               49,048                 Proteinuria              0                          43,859      2,385     5,189     332
  Yanik et al (2010)                    US        1998-2008         4,376                900                    Proteinuria              0                          129         13        772       210
  Butt et al (C.-C.) (2011)             US        2001-2006         68,285               43,139                 eGFR\<60 ml/min/1.73m2   0                          25,137      3,738     18,002    3,140
  Satapathy et al (eGFR\<60) (2012)     US        2003-2006         2,415                865                    eGFR\<60 ml/min/1.73m2   0                          313         16        552       53
  Li et al (2014)                       Taiwan    2010-2011         24,642               24,642                 eGFR\<60 ml/min/1.73m2   0                          22,943      1,398     1,699     280
  Kurbanova (2015)                      US        1999-2012         33,729               33,729                 eGFR\<60 ml/min/1.73m2   0                          33,070      3,523     659       50
  Kurbanova (Proteinuria) (2015)        US        1999-2012         33,729               33,729                 Proteinuria              0                          33,070      4,183     659       112
  **Longitudinal studies**                                                                                                                                                                          
  Tsui et al (eGFR\<15) (L.) (2007)     US        2000-2001         2,352,584            474,369                eGFR\<15 ml/min/1.73m2   3.4                        421,495     4,393     52,874    760
  Moe et al (Long.) (2008)              US        1994-2004         19,303               7,038                  eGFR\<60 ml/min/1.73m2   3.5                        4,795       NR        2,243     NR
  Asrani et al (eGFR\<60) (L) (2010)    US        2003-2006         6,000,000            88,822                 eGFR\<60 ml/min/1.73m2   2.1                        80,759      2,826     8,063     306
  Asrani et al (eGFR\<30) (L) (2010)    US        2003-2006         6,000,000            88,822                 eGFR\<30 ml/min/1.73m2   2.1                        80,759      56        8,063     10
  Asrani et al (eGFR\<15) (L) (2010)    US        2003-2006         6,000,000            88,822                 eGFR\<15 ml/min/1.73m2   2.1                        80,759      8         8,063     2
  Butt et al (Long.) (2011)             US        2001-2006         68,285               43,139                 eGFR\<60 ml/min/1.73m2   3.15                       25,137      NR        18,002    NR
  Hofmann et al (2011)                  Europe    1990-2006         258,000              223,536                eGFR\<60 ml/min/1.73m2   9.3                        198,124     443       25,412    208
  Satapathy et al (eGFR\<15) (2012)     US        2003-2006         2,415                865                    eGFR\<15 ml/min/1.73m2   7                          313         2         552       15
  Peters et al (2012)                   Europe    1994-2011         16,594               8,235                  eGFR\<60 ml/min/1.73m2   4.39                       6,183       375       2,052     120
  Su et al (2012)                       Taiwan    2000-2005         1,000,000            37,746                 eGFR\<15 ml/min/1.73m2   5.58                       31,455      196       6,291     77
  Chen et al (2013)                     Taiwan    1998-2004         1,000,000            15,910                 eGFR\<60 ml/min/1.73m2   5.92                       12,728      187       3,182     64
  Chen et al (2014)                     Taiwan    1996-2010         1,000,000            47,150                 eGFR\<60 ml/min/1.73m2   7.43                       37,720      960       9,430     367
  Lee et al (2014)                      Taiwan    2002-2009         4,321                4,185                  eGFR\<60 ml/min/1.73m2   2.2                        3,868       891       317       118
  Molnar et al (eGFR\<60) (2015)        US        2004-2006         4,444,699            1,021,049              eGFR\<60 ml/min/1.73m2   8                          920,531     95,837    100,518   11,271
  Molnar et al (eGFR\<15) (2015)        US        2005-2006         4,444,699            1,021,049              eGFR\<15 ml/min/1.73m2   8                          920,531     2,479     100,518   904

Note. (C): cross-sectional studies; (L): longitudinal studies; CKD, chronic kidney disease; eGFR: estimated glomerular filtration rate; NR: not reported.

###### The baseline characteristics of all study populations included in this meta-analysis

  Author (Index) (year)                 EE\*; 95% CI       Adj-EE\*; 95% CI   Age (years)   Male (%)   DM      Hypertension                           
  ------------------------------------- ------------------ ------------------ ------------- ---------- ------- -------------- ------- ------- ------- -------
  **Cross-sectional studies**                                                                                                                         
  Liangpunsakul (2005)                  1.51; 1.67-2.15    1.99; 1.38-2.85    43            43         61      62             4.7     10.5    25      32
  Huang et al (2006)                    1.52; 1.15-2.03    NR                 55.2          55.2       43.2    43.2           12.5    12.5    33.4    33.4
  Tsui et al (2006)                     0.45; 0.24-0.85    0.89; 0.49-1.62    NR            NR         47.00   67.00          5.00    5.00    31.00   27.00
  Tsui et al (Proteinuria) (2006)       1.29; 0.86-1.93    1.38; 0.91-2.07    NR            NR         47.00   67.00          5.00    5.00    31.00   27.00
  Dalrymple et al (2007)                1.08; 0.88-1.33    1.08; 0.88-1.33    58.00         53.00      91.00   96.00          22.00   19.00   69.00   61.00
  Tsui et al (eGFR\<60) (C) (2007)      0.48; 0.47-0.50    NR                 59.00         52.00      94.00   97.00          26.00   21.00   59.00   47.00
  Tsui et al (eGFR\<30) (C) (2007)      1.00; 0.94-1.07    NR                 59.00         52.00      94.00   97.00          26.00   21.00   59.00   47.00
  Ishizaka et al (2008)                 2.46; 1.54-3.94    1.83; 1.10-3.05    53.1          59.2       64.19   62.5           NR      NR      NR      NR
  Ishizaka et al (Proteinuria) (2008)   2.33; 1.30-4.19    2.00; 1.06-3.76    53.1          59.2       64.19   62.5           NR      NR      NR      NR
  Moe et al (C.-C.) (2008)              0.76; 0.66-0.89    0.69; 0.62-0.77    41.20         43.60      44.10   60.40          22.60   23.40   46.50   50.80
  Asrani et al (eGFR\<60) (C) (2010)    0.92; 0.79-1.08    0.92; 0.79-1.08    40.40         47.80      43.80   60.10          6.70    9.60    7.60    9.70
  Asrani et al (eGFR\<30) (C) (2010)    0.90; 0.62-1.32    NR                 40.40         47.80      43.80   60.10          6.70    9.60    7.60    9.70
  Asrani et al (eGFR\<15) (C) (2010)    1.22; 0.69-2.16    NR                 40.40         47.80      43.80   60.10          6.70    9.60    7.60    9.70
  Gordon et al (2010)                   1.46; 1.31-1.62    NR                 48.00         52.00      48.20   62.30          NR      NR      NR      NR
  Lee et al (eGFR\<60) (2010)           1.36; 1.27-1.46    1.26; 1.17-1.38    60.80         64.30      31.00   29.30          9.70    10.50   31.00   32.70
  Lee et al (eGFR\<30) (2010)           1.43; 1.07-1.90    NR                 60.80         64.30      31.00   29.30          9.70    10.50   31.00   32.70
  Lee et al (Proteinuria) (2010)        1.19; 1.06-1.34    1.14; 1.00-1.3     60.80         64.30      31.00   29.30          9.70    10.50   31.00   32.70
  Yanik et al (2010)                    2.07; 1.59-4.58    1.84; 1.03-3.27    48.9          48.9       65.4    65.4           10.8    10.8    38.7    38.7
  Butt et al (C.-C.) (2011)             1.21; 1.15-1.27    NR                 52.80         51.90      97.30   97.30          26.60   22.90   60.80   52.40
  Satapathy et al (eGFR\<60) (2012)     1.97; 1.11-3.51    NR                 50.00         50.00      64.20   68.30          16.30   19.00   37.40   39.30
  Li et al (2014)                       1.24; 1.05-1.48    1.24; 1.05-1.48    41.70         42.40      52.80   42.40          NR      NR      NR      NR
  Kurbanova (2015)                      0.69; 0.47-1.02    0.88; 0.57-1.37    49.5          50.8       48      63.9           12.2    14.4    36.4    43.7
  Kurbanova (Proteinuria) (2015)        1.40; 1.08-1.81    1.50; 1.08-2.08    49.5          50.8       48      63.9           12.2    14.4    36.4    43.7
  **Longitudinal studies**                                                                                                                            
  Tsui et al (eGFR\<15) (L.) (2007)     1.39; 1.28-1.50    1.68; 1.54-1.82    59.00         52.00      94.00   97.00          26.00   21.00   59.00   47.00
  Moe et al (Long.) (2008)              0.90; 0.79-1.02    0.90; 0.79-1.02    41.30         44.10      45.40   58.20          18.20   19.90   41.70   44.70
  Asrani et al (eGFR\<60) (L) (2010)    1.09; 0.97-1.23    NR                 43.20         48.70      40.80   59.20          10.30   12.40   11.10   12.30
  Asrani et al (eGFR\<30) (L) (2010)    1.79; 0.91-3.51    NR                 43.20         48.70      40.80   59.20          10.30   12.40   11.10   12.30
  Asrani et al (eGFR\<15) (L) (2010)    2.50; 0.53-11.8    NR                 43.20         48.70      40.80   59.20          10.30   12.40   11.10   12.30
  Butt et al (Long.) (2011)             1.30; 1.23-1.37    1.30; 1.23-1.37    52.80         51.90      97.30   97.30          26.60   22.90   60.80   52.40
  Hofmann et al (2011)                  3.68; 3.12-4.34    NR                 NR            37.60      69.10   69.10          NR      3.70    NR      NR
  Satapathy et al (eGFR\<15) (2012)     4.34; 0.99-19.12   NR                 50.00         50.00      64.20   68.30          16.30   19.00   37.40   39.30
  Peters et al (2012)                   0.96; 0.78-1.19    NR                 42.00         39.00      75.90   67.80          4.80    3.70    25.90   14.70
  Su et al (2012)                       1.53; 1.17-2.01    1.53; 1.17-2.01    NR            NR         50.50   50.50          NR      NR      NR      NR
  Chen et al (2013)                     1.75; 1.27-2.43    1.75; 1.27-2.43    NR            NR         50.90   50.90          7.70    0.00    13.60   0.00
  Chen et al (2014)                     1.28; 1.12-1.46    1.28; 1.12-1.46    NR            NR         49.60   49.60          14.40   25.20   28.60   34.10
  Lee et al (2014)                      1.32; 1.07-1.62    1.32; 1.07-1.62    61.77         64.53      59.40   47.60          35.60   43.50   11.10   9.20
  Molnar et al (eGFR\<60) (2015)        1.15; 1.12-1.17    1.15; 1.12-1.17    55.00         53.00      92.00   96.00          21.00   21.00   54.00   53.00
  Molnar et al (eGFR\<15) (2015)        1.98; 1.81-2.16    1.98; 1.81-2.16    55.00         53.00      92.00   96.00          21.00   21.00   54.00   53.00

Note. (C): cross-sectional studies; (L): longitudinal studies; Unexpo.: unexposed; Expo.: exposed; eGFR: estimated glomerular filtration rate; EE: effect estimate; Adj-EE: adjusted effect estimate; 95% CI: 95% confidence interval; NR: not reported. \*EE refers to odds ratio in cross-sectional studies and hazard ratio in longitudinal studies.

The number of studies testing the prevalence or incidence of proteinuria, eGFR \< 60, \< 30 and \< 15 ml/min/1.73m^2^ was 7, 21, 4 and 6, respectively. Twenty-five of 38 studies were conducted in the U.S., 9 in Taiwan, 2 in Japan and 2 in European countries. Adjusted effect estimate and its 95% CI were reported in 23 studies. In 15 longitudinal studies, the median follow-up period ranged from 2.1 years \[[@R9]\] to 9.3 years \[[@R8]\].

Effect estimates {#s2_2}
----------------

Considering the methodological distinction between cross-sectional and longitudinal studies, we analyzed them separately in this study. To avoid repeated incorporation, only study with eGFR \< 60 ml/min/1.73m^2^ was retained in case of different eGFR cutoffs recorded in the same article, and there were 12 and 15 unduplicated studies with longitudinal and cross-sectional designs, respectively. Overall effect estimate was remarkably significant in longitudinal studies (HR, 95% CI, *P* : 1.45, 1.23-1.71, \< 0.001), in contrast to that in cross-sectional studies (OR, 95% CI, *P* : 1.25, 0.90-1.73, 0.188), while there was strong evidence of heterogeneity (both *I*^2^ \> 95%) (Figure [1](#F1){ref-type="fig"}). The power to identify the significant association in longitudinal studies was over 99.9%. After restricting analysis to the studies with adjusted effect estimates, the magnitude of risk was weakened, but significance was still persisted in 8 longitudinal studies (HR, 95% CI, *P* : 1.31, 1.15-1.48, \< 0.001), relative to that in 10 cross-sectional studies (OR, 95% CI, *P* : 1.15, 0.93-1.43, 0.197), with obvious heterogeneity (both *I*^2^ \> 90%).

To investigate the impact of specific clinical differences between studies, we performed a set of stratified analyses according to CKD subtype, country and median follow-up period (for longitudinal studies only), respectively (Table [3](#T3){ref-type="table"}). By CKD subtype, the analysis was based on 38 studies as mentioned above. HCV infection was associated with an 1.54-fold increased risk (OR, 95% CI, *P* : 1.54, 1.27-1.87, \< 0.001) of having proteinuria in 7 cross-sectional studies, while no significance was observed in studies with eGFR of different cutoffs (*P* \> 0.05). In longitudinal studies, a graded increased risk for incident CKD was noticed with reduced eGFR, that is, for eGFR of less than 60, 30 and 15 ml/min/1.73m^2^, the corresponding HR was 1.39 (95% CI, P: 1.14-1.69, 0.001) in 9 studies, 1.79 (95% CI, P: 0.91-3.51, 0.091) in 1 study and 2.30 (95% CI, P: 1.26-4.19, 0.007) in 5 studies, and there was no improvement in heterogeneity.

###### Summary on stratified analyses according to country, CKD definition and median follow-up period respectively in cross-sectional and longitudinal studies

  Subgroups                       Cross-sectional studies   Longitudinal studies                                              
  ------------------------------- ------------------------- -------------------------- ------- --- -------------------------- -------
  ***Country***                                                                                                               
  East Asia                       4                         1.99, 1.23-3.20, 0.005     96.7%   4   1.69, 1.44-1.98, \<0.001   54.2%
  U.S.                            11                        1.04, 0.74-1.48, 0.811     99.2%   6   1.15, 1.02-1.31, 0.026     92.8%
  Europe                          0                         NR                         NR      2   1.89, 0.51-7.03, 0.345     99.0%
  ***CKD definition***                                                                                                        
  Proteinuria                     7                         1.54, 1.27-1.87, \<0.001   68.7%   0   NR                         NR
  eGFR \<60 ml/min/1.73m2         12                        1.11, 0.77-1.60, 0.567     99.4%   9   1.39, 1.14-1.69, 0.001     97.3%
  eGFR \<30 ml/min/1.73m2         3                         1.08, 0.86-1.38, 0.502     67.1%   1   1.79, 0.91-3.51, 0.091     NR
  eGFR \<15 ml/min/1.73m2         1                         1.22, 0.69-2.16, 0.500     NR      5   2.30, 1.26-4.19, 0.007     98.4%
  ***Median follow-up period***                                                                                               
  \<5 years                       NR                        NR                         NR      6   1.21, 1.03-1.43, 0.024     92.0%
  ≥5 years                        NR                        NR                         NR      6   1.86, 1.19-2.89, 0.006     98.1%

Notes. CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; OR: odds ratio; HR: hazard ratio; 95% CI: 95% confidence interval; I2: inconsistency index; NR: not reported.

By country, the presence of HCV infection was associated with an 1.99-fold (95% CI, *P* : 1.23-3.20, 0.005) and 1.69-fold (95% CI, *P* : 1.44-1.98, \< 0.001) increased risk of the prevalent (4 cross-sectional studies) and incident (4 longitudinal studies) CKD in East Asian countries (Taiwan and Japan), respectively (Table [3](#T3){ref-type="table"}). Moreover in 6 U.S. longitudinal studies, the risk for incident CKD was marginally significant (HR, 95% CI, P: 1.15, 1.02-1.31, 0.026) and *I*^2^ was 92.8%. When the longitudinal studies were further grouped by median follow-up time at 5 years, the effect estimate was reinforced in long-term studies (HR, 95% CI, P: 1.86, 1.19-2.89, 0.006; *I*^2^ = 98.1%) relative to that in short-term studies (HR, 95% CI, P: 1.21, 1.03-1.43, 0.024; *I*^2^ = 92.0%).

Meta-regression analyses {#s2_3}
------------------------

First, we one by one modeled all possible confounders including age, gender, diabetes mellitus, hypertension, country, CKD subtype and follow-up period (for longitudinal studies only), and interestingly found that the risk for incident CKD was significantly associated with the increased percentages of males (*P* = 0.020) and diabetes mellitus (*P* = 0.005), as well as the reduced eGFR (*P* = 0.017) and increased follow-up time (*P* = 0.002, Figure [2](#F2){ref-type="fig"}). We next modeled all possible confounders simultaneously and failed to detect any observable significance, which was likely attributed to the fact that meta-regression did not have the methodological rigor of a properly-designed study that was intended to test the effect of these covariates formally despite its capability to consider various covariates \[[@R31]\].

![Correlation plot of median follow-up time with effect estimates in longitudinal studies](oncotarget-08-10692-g002){#F2}

Publication bias {#s2_4}
----------------

The filled funnel plots that reflected the evidence of selective publication are provided in Figure [3](#F3){ref-type="fig"}. The Egger\'s test suggested a marginally significant probability of publication bias for both longitudinal studies (*P* = 0.054) and cross-sectional (*P* = 0.064). As estimated, there were respectively 3 and 6 missing studies required to make the filled funnel plots symmetrical in longitudinal and cross-sectional studies. To account for the impact of these possible missing studies on the overall effect estimates, we employed the trim-and-fill analysis and identified a reduced risk conferred by HCV infection for prevalent CKD in simulated 21 cross-sectional studies (OR, 95% CI, P: 0.79, 0.59-1.06, 0.121), but an increased risk for incident CKD in simulated 16 longitudinal studies (HR, 95% CI, P: 1.16, 0.96-1.39, 0.118).

![The filled funnel plots for the prevalence and incidence of CKD conferred by the presence of HCV infection\
Actual studies are denoted by the hollow circles, and potential missing studies in need to achieve symmetry are denoted by the solid squares. The theta in the y-axis represents the log(odds ratio) for cross-sectional studies and the log(hazard ratio) for longitudinal studies. The s.e. of theta in the x-axis represents the standard error of log(odds ratio or hazard ratio).](oncotarget-08-10692-g003){#F3}

DISCUSSION {#s3}
==========

The most noteworthy finding of this meta-analysis is the significant risk of experiencing incident CKD after HCV infection, with the lower eGFR and longer HCV exposure time entailing a greater risk. As far as we know, this is to-date the largest comprehensive met-analysis that has assessed the predisposition of HCV exposure to the occurrence and severity of CKD in the current literature.

As opposed to the significant effect estimate in cross-sectional studies in the latest meta-analysis by Park et al \[[@R11]\], we utilized a large sample size and failed to support the contributory role of HCV infection in the prevalence of CKD, in agreement with another recent more comprehensive meta-analysis by Fabrizi et al \[[@R12]\]. Although we and Fabrizi et al \[[@R12]\] both observed the independent predictive capability of HCV infection for prevalent proteinuria, we additionally identified a graded risk for incident CKD with the lower eGFR and longer HCV exposure time. This tendency is clinically plausible as HCV infection was associated with a wide range of extra-hepatic manifestations in various organs including the kidneys and it is highly prevalent among CKD patients under hemodialysis and in kidney transplantation recipients \[[@R32]\]. Also this finding lent some indirect credence for the likely detrimental impact of HCV infection in the development of CKD. In theory, several possible pathways have been proposed for the predisposition of HCV to extra-hepatic manifestations. Experimental data indicated that HCV can be conveyed by infected B-lymphocytes or exosomes to enter renal tissue for replication \[[@R33], [@R34]\] and cause kidney injury through cryoglobulins, HCV-antibody immune complexes, or amyloid deposition \[[@R5]\]. Moreover, many ingredients required for HCV attachment were found to be abundantly expressed in renal parenchyma \[[@R5]\]. Although the exact molecular mechanisms of how HCV infection entails the risk of CKD remain unclear, it is possible that systemic immune response to HCV infection might be one of the pathophysiological mechanisms.

A note of caution, however, should be made when interpreting our findings, because unexpectedly HCV exposure was nonsignificantly associated with the prevalence of CKD when analysis was restricted to cross-sectional studies. Some studies even observed that HCV infection was a protective factor for the prevalence of CKD \[[@R6], [@R7], [@R15], [@R16], [@R30]\]. By contrast in longitudinal studies, HCV-infected individuals had a 45% significantly increased risk of experiencing incident CKD after adjusting for traditional risk factors during 2 to 9 years of follow-up and even restricting analysis to multivariate-adjusted effect estimates. Actually, it is not uncommon in the literature to encounter such divergence between longitudinal and cross-sectional designs, even in the same study population. For example, HCV infection was associated with an increased risk of incident end stage renal disease (ESRD, eGFR \< 15 ml/min/1.73m^2^), but a reduced risk of prevalent CKD (eGFR \< 60 ml/min/1.73m^2^) in the study by Tsui et al \[[@R16]\]. A possible explanation for this case is that most sources of error due to confounding and bias are more common in cross-sectional studies than in longitudinal studies. For this reason, the findings from cross-sectional studies are often criticized. Moreover, such divergence between longitudinal and cross-sectional studies may also be proposed as a rational explanation for the negative correlation between HCV infection and CKD risk observed in the previous meta-analysis by Fabrizi et al \[[@R10]\].

Several possible limitations should be acknowledged for the interpretation of our meta-analytical findings. Firstly, we selected eligible studies from only English-language literature, and some well-designed studies published in the other languages might introduce a possible selection bias. Secondly, we cannot fully rule out all potential biases due to the unavailability of individual participant data in this study. Thirdly, although stratified and meta-regression analyses were conducted to explore and interpret diversity among the results of different studies, there was still no material improvement in heterogeneity. Fourthly, both filled funnel plots and Egger\'s tests indicated moderate evidence of publication bias; however taking into account the number and potential outcome of missing studies in the trim-and-fill analysis still produced significant effect sizes. Fifthly, it must be emphasized that nearly all eligible studies in this meta-analysis were conducted in the U.S. and Taiwan, thus the application of our findings cannot be extrapolated to populations in other continents.

In conclusion, this meta-analysis of 22 articles provides strong evidence for the significant risk of experiencing incident CKD after HCV infection, with the lower eGFR and longer HCV exposure time entailing a greater risk. It is of clinical importance to elucidate the molecular mechanisms underlying the HCV infection-CKD relationship, which will constitute an extremely promising field in life sciences. Importantly, treatment of HCV infection in CKD patients still remains a clinical challenge.

MATERIALS AND METHODS {#s4}
=====================

Checklist {#s4_1}
---------

The conduct of this meta-analysis adheres to the guidelines listed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R35]\] (see the PRISMA checklist in [Supporting Table S1](#SD2){ref-type="supplementary-material"}).

Search strategies {#s4_2}
-----------------

To ensure comprehensive literature coverage, we searched electronic databases including Medline (PubMed), EMBASE, Web of Science and Google-Scholar as of July 14, 2016 using the key terms 'hepatitis C', 'HCV', 'anti-HCV positive status', 'chronic kidney disease', 'renal disease', 'CKD', 'renal/kidney impairment', 'renal/kidney insufficiency', 'renal/kidney failure', 'proteinuria' and 'microalbuminuria'. As a primary need, all potential articles gathered must be published in English language and performed in human beings. The reference lists of major original articles and reviews were manually checked to avoid potential missing hits.

Inclusion criteria {#s4_3}
------------------

The retrieved article was included if a cross-sectional or longitudinal study was designed to assess the incidence or prevalence of CKD or its graded stages in HCV-infected patients in comparison with controls who were not infected by HCV. The primary effect size was, if available, the ultimately-adjusted odds ratio (OR) or hazard ratio (HR) and the corresponding 95% confidence interval (95% CI), or was derived from a 2×2 contingency table with the counts of subjects with and without CKD under the presence or absence of HCV infection.

Article selection {#s4_4}
-----------------

Based on pre-determined selection criteria, two authors (Min Li and Peiyuan Wang) independently identified eligible articles by reviewing the title or abstract of each retrieved article and if necessary the full text. If an article provided data on the basis of both cross-sectional and longitudinal scenarios or specific CKD stages, each was analyzed separately.

Data abstraction {#s4_5}
----------------

From each eligible article, two authors (Min Li and Peiyuan Wang) were in charge of abstracting pre-determined relevant information according to the results of within-group discussion and for the sake of accuracy this process was independently completed and checked for consistency. Any disagreement was settled with a consensus reached.

Abstracted data included first author\'s surname, year in publication, cohort or population name, follow-up time, the country where study subjects were enrolled, race/ethnicity, sample size, study design, the cutoff of eGFR to define CKD, adjusted effect estimate and its 95% CI, the counts of subjects with and without CKD under the presence or absence of HCV infection, age, gender, hypertension and diabetes mellitus if available.

Statistical analyses {#s4_6}
--------------------

The effect-size estimate of each independent study was summarized in random-effects model that used the DerSimonian and Laird method \[[@R36]\]. The magnitude of between-study heterogeneity was represented by inconsistency index (I^2^) statistic, which is defined as the percentage of observed variability between studies that can be explained by heterogeneity rather than a chance finding. Stratified analyses by study design (cross-sectional studies and longitudinal studies), country (the U.S., East Asia and Europe) and median follow-up time (in longitudinal studies only: short-term: \< 5 years and long-term: ≥ 5 years). Meta-regression analyses were further conducted to account for potential sources of clinical heterogeneity. The probability of publication bias was visually inspected by the filled funnel plots and statistically examined by the Egger\'s test at a significance level of 5%. The meta-analytical programs implemented in STATA software (StataCorp, TX, version 13.0) were employed for above statistical analyses. In addition, study power was estimated by the Power and Sample Size Calculations (PS) software (version 3.0) \[[@R37]\].
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